prednisone has been researched along with AIDS-Associated Lymphoma in 131 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma." | 9.13 | Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. ( Abella, E; García, M; Gardella, S; González-Barca, E; López, A; López-Guillermo, A; Miralles, P; Morgades, M; Oriol, A; Ribera, JM, 2008) |
| "Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma." | 5.13 | Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. ( Abella, E; García, M; Gardella, S; González-Barca, E; López, A; López-Guillermo, A; Miralles, P; Morgades, M; Oriol, A; Ribera, JM, 2008) |
| "The proportion of intravenous drug abusers (IVDA) in HIV-HD (38%) is higher than in French HIV-infected population as a whole (20." | 3.78 | Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. ( Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM, 1995) |
| " We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy." | 3.74 | Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. ( Bergsagel, DJ; Crosswell, HE; Lew, G; Yost, R, 2008) |
| " In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP." | 3.73 | The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. ( Feliu, E; Lloveras, N; Mate, JL; Navarro, JT; Oriol, A; Ribera, JM, 2005) |
| "Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/m(2) was given with fixed doses of cyclophosphamide, vincristine, and prednisone every 21 days." | 2.71 | Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. ( Boswell, WD; Espina, B; Levine, AM; Lieberman, RD; Nathwani, BN; Sherrod, A; Tulpule, A; Welles, L, 2004) |
| "Complete pharmacokinetics and pharmacodynamic analysis was determined in 19 patients during 38 cycles of chemotherapy: 19 cycles with CHOP and 19 CHOP + HAART in a crossover-designed study." | 2.71 | Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. ( Boiocchi, M; Cattarossi, G; Corona, G; Di Gennaro, G; Tirelli, U; Toffoli, G; Vaccher, E, 2004) |
| " In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART." | 2.70 | Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ( Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001) |
| "Prophylaxis against Pneumocystis carinii pneumonia (PCP) and candida were given routinely." | 2.67 | Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. ( Brandwein, J; Burkes, RL; Sawka, CA; Shepherd, FA; Sutton, DM; Warner, E, 1992) |
| "Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma." | 2.49 | Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. ( Barta, SK; Boue, F; Dunleavy, K; Galicier, L; Garcia, O; Kaplan, LD; Lee, JY; Little, RF; Morgades, M; Mounier, N; Navarro, JT; Noy, A; Oriol, A; Ratner, L; Remick, SC; Ribera, JM; Sparano, JA; Spina, M; Tamari, R; Tirelli, U; Wang, D; Weiss, R; Wilson, WH; Wyen, C; Xue, X, 2013) |
| "Four patients had a prior AIDS diagnosis." | 2.39 | Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol. ( Grünewald, T; Jautzke, G; Pohle, HD; Ruf, B; Schürmann, D; Weiss, R, 1995) |
| "Here we present a case of plasmablastic lymphoma with primary site being maxillary sinus, a rare location." | 1.43 | Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS. ( Basavaraj, A; Kadam, DB; Kadam, M, 2016) |
| "Among these patients, 7 had Burkitt lymphoma (BL), 20 had diffuse large B cell lymphoma (DLBCL), 7 had plasmablastic lymphoma (PL), and 1 had primary effusion lymphoma (PEL)." | 1.40 | Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era. ( Adamski, M; Gunthel, C; Mosunjac, M; Nguyen, ML; Silverton, A, 2014) |
| "Hodgkin lymphomas (HL) and non Hodgkin lymphomas (NHL) are frequently associated to acquired immunodeficiency syndrome in adults." | 1.39 | [Lymphomas associated with HIV infection in patients at the Hospital San Borja Arriarán /Fundación Arriarán 2001-2008, Santiago, Chile]. ( Carmona, J; Cortés, C; García, H; Pizarro, A; Riquelme, A, 2013) |
| "Two-year OS for patients with AIDS-related DLBCL treated with CHOP like regimens and cART is comparable to that seen in the United States and Europe." | 1.39 | Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa. ( de Witt, P; Maartens, DJ; Sissolak, G; Uldrick, TS, 2013) |
| "AIDS-related Burkitt's lymphoma or leukemia (BLL) is increasingly treated with specific and intensive multiagent schedules." | 1.37 | Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. ( Brunet, S; de la Torre, J; Esteve, J; Hoelzer, D; La Cruz, J; Mahillo, B; Miralles, P; Morgades, M; Oriol, A; Ribera, JM; Téllez, MJ; Valencia, E; Xicoy, B, 2011) |
| "Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases." | 1.34 | AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. ( Campbell, LJ; Dawson, MA; McLean, C; Oei, P; Schwarer, AP; Shortt, J; Street, AM; Wright, E, 2007) |
| "Hodgkin lymphoma is considered a common type of non-AIDS defining tumor among patients infected with HIV, commonly presenting as a widespread disease and with different pathologic features compared with Hodgkin lymphoma in the general population." | 1.34 | Hodgkin lymphoma among patients infected with HIV in post-HAART era. ( Buccheri, V; Calore, EE; Chamone, DA; Pessoa, VP; Pracchia, LF; Tanaka, PY, 2007) |
| "The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has improved since the era of highly active antiretroviral therapy, but median survival remains low." | 1.32 | Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. ( Franchini, G; Grant, N; Gutierrez, M; Jaffe, ES; Kavlick, MF; Little, RF; Mitsuya, H; Pittaluga, S; Raffeld, M; Shearer, G; Steinberg, SM; Wilson, WH; Yarchoan, R, 2003) |
| "A 35-year-old man who, as a result of intravenous drug abuse, had become infected with HIV 18 years previously, was admitted with signs of right-heart failure." | 1.31 | [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. ( Baumgart, D; Gerken, G; Noppeney, R; Reimer, J; Ross, B; Sadony, V; Sturm, A; Sundermann, T, 2001) |
| "A prior AIDS-defining opportunistic infection was reported in 35 patients (70%)." | 1.31 | Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. ( Dharmapala, D; Espina, BM; Gill, PS; Levine, AM; Sanchez, MN; Sherrod, A; Tulpule, A; Young, LL, 2002) |
| "Burkitt's lymphoma is a rare aggressive lymphoma, which responds poorly to standard chemotherapy regimens used to treat high-grade non-Hodgkin's lymphoma (NHL)." | 1.31 | Burkitt's lymphoma: single-centre experience with modified BFM protocol. ( Harris, E; Jackson, N; Jones, L; Mahendra, P; Paneesha, S, 2002) |
| "The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event." | 1.29 | Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. ( Brody, J; Goh, JC; Kaplan, MH; Koduru, P; Lichtman, SM; Susin, M, 1993) |
| "We describe a patient with acquired immunodeficiency syndrome (AIDS) and non-Hodgkin's lymphoma of the duodenum manifested as obstructive jaundice." | 1.29 | Primary small bowel lymphoma manifested as obstructive jaundice in a patient with AIDS. ( Bresalier, RS; Schoeppner, HL; Wong, DK, 1995) |
| "After confirming the diagnosis of Burkitt's lymphoma, they were treated according to conventional protocols, with no need to reduce the dose intensity." | 1.29 | Favorable response of pediatric AIDS-related Burkitt's lymphoma treated by aggressive chemotherapy. ( Ben-Bassat, I; Mandel, M; Martinowitz, U; Neumann, Y; Ramot, B; Rechavi, G; Toren, A; Varon, D, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (21.37) | 18.2507 |
| 2000's | 69 (52.67) | 29.6817 |
| 2010's | 33 (25.19) | 24.3611 |
| 2020's | 1 (0.76) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos, JC | 2 |
| Sparano, JA | 5 |
| Chadburn, A | 3 |
| Reid, EG | 2 |
| Ambinder, RF | 4 |
| Siegel, ER | 1 |
| Moore, PC | 1 |
| Rubinstein, PG | 1 |
| Durand, CM | 1 |
| Cesarman, E | 3 |
| Aboulafia, D | 1 |
| Baiocchi, R | 1 |
| Ratner, L | 4 |
| Kaplan, L | 2 |
| Capoferri, AA | 1 |
| Lee, JY | 6 |
| Mitsuyasu, R | 3 |
| Noy, A | 4 |
| Hunter, NB | 1 |
| Vogt, S | 1 |
| Milligan, MG | 1 |
| Bigger, E | 1 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Zola, M | 1 |
| Kayembe, MKA | 1 |
| Medhin, H | 1 |
| Suneja, G | 1 |
| Lockman, S | 1 |
| Chabner, BA | 1 |
| Dryden-Peterson, SL | 1 |
| Pizarro, A | 1 |
| García, H | 1 |
| Riquelme, A | 1 |
| Carmona, J | 1 |
| Cortés, C | 1 |
| Aurer, I | 1 |
| Bašić-Kinda, S | 1 |
| Radman, I | 1 |
| Ilić, I | 1 |
| Grah, JJ | 1 |
| de Witt, P | 1 |
| Maartens, DJ | 1 |
| Uldrick, TS | 1 |
| Sissolak, G | 1 |
| Tanaka, S | 1 |
| Nagata, N | 1 |
| Mine, S | 1 |
| Igari, T | 1 |
| Kobayashi, T | 1 |
| Sugihara, J | 1 |
| Honda, H | 1 |
| Teruya, K | 2 |
| Kikuchi, Y | 1 |
| Oka, S | 2 |
| Uemura, N | 1 |
| Barta, SK | 2 |
| Xue, X | 1 |
| Wang, D | 1 |
| Tamari, R | 1 |
| Mounier, N | 1 |
| Kaplan, LD | 6 |
| Ribera, JM | 9 |
| Spina, M | 4 |
| Tirelli, U | 8 |
| Weiss, R | 3 |
| Galicier, L | 2 |
| Boue, F | 2 |
| Wilson, WH | 2 |
| Wyen, C | 4 |
| Oriol, A | 8 |
| Navarro, JT | 6 |
| Dunleavy, K | 1 |
| Little, RF | 3 |
| Garcia, O | 1 |
| Morgades, M | 3 |
| Remick, SC | 1 |
| Levine, AM | 7 |
| Kojima, Y | 1 |
| Hagiwara, S | 2 |
| Uehira, T | 2 |
| Ajisawa, A | 2 |
| Kitanaka, A | 1 |
| Tanuma, J | 2 |
| Okada, S | 3 |
| Nagai, H | 2 |
| Silverton, A | 1 |
| Gunthel, C | 1 |
| Adamski, M | 1 |
| Mosunjac, M | 1 |
| Nguyen, ML | 1 |
| Hentrich, M | 3 |
| Hoffmann, C | 3 |
| Mosthaf, F | 2 |
| Müller, M | 2 |
| Siehl, J | 2 |
| Hensel, M | 1 |
| Shah, NN | 1 |
| Harrison, N | 1 |
| Stonecypher, M | 1 |
| Frank, D | 1 |
| Amorosa, V | 1 |
| Svoboda, J | 1 |
| Pereira, R | 1 |
| Carvalho, J | 1 |
| Patrício, C | 1 |
| Farinha, P | 1 |
| Epeldegui, M | 1 |
| Martínez, AC | 1 |
| Widney, DP | 1 |
| Magpantay, LI | 1 |
| Regidor, D | 1 |
| Martínez-Maza, O | 1 |
| Koizumi, Y | 1 |
| Ota, Y | 1 |
| Ogawa, Y | 1 |
| Yajima, K | 1 |
| Yotsumoto, M | 1 |
| Ikegaya, S | 1 |
| Watanabe, D | 1 |
| Minamiguchi, H | 1 |
| Hodohara, K | 1 |
| Murotani, K | 1 |
| Mikamo, H | 1 |
| Wada, H | 1 |
| Shirasaka, T | 1 |
| Kodama, Y | 1 |
| Hishima, T | 1 |
| Mochizuki, M | 1 |
| Katano, H | 2 |
| Basavaraj, A | 1 |
| Kadam, M | 1 |
| Kadam, DB | 1 |
| Zahiu, DC | 1 |
| Mocanu, C | 1 |
| Rimbaş, M | 1 |
| Castillo, J | 1 |
| Pantanowitz, L | 2 |
| Dezube, BJ | 3 |
| Zaragoza, V | 1 |
| Martínez, L | 1 |
| Pérez-Ferriols, A | 1 |
| Alegre, V | 1 |
| Crutchlow, E | 1 |
| Miombe, Y | 1 |
| Latham, T | 1 |
| Martí-Carvajal, AJ | 1 |
| Cardona, AF | 1 |
| Lawrence, A | 1 |
| Lerner, A | 1 |
| Soto, J | 1 |
| Rosen, JE | 1 |
| Fulco, PP | 1 |
| Hynicka, L | 1 |
| Rackley, D | 1 |
| Castillo, JJ | 2 |
| Winer, ES | 1 |
| Stachurski, D | 1 |
| Perez, K | 1 |
| Jabbour, M | 1 |
| Milani, C | 1 |
| Colvin, G | 1 |
| Butera, JN | 1 |
| Ridha, E | 1 |
| Cookson, H | 1 |
| Devitt, E | 1 |
| Nelson, M | 1 |
| Suzuki, K | 1 |
| Nakazato, T | 1 |
| Sanada, Y | 1 |
| Mihara, A | 1 |
| Tachikawa, N | 1 |
| Kurai, H | 1 |
| Yoshimura, Y | 1 |
| Hayashi, H | 1 |
| Yoshida, S | 1 |
| Kakimoto, T | 1 |
| Xicoy, B | 2 |
| Miralles, P | 2 |
| La Cruz, J | 1 |
| Valencia, E | 1 |
| Mahillo, B | 1 |
| de la Torre, J | 1 |
| Téllez, MJ | 1 |
| Brunet, S | 2 |
| Esteve, J | 2 |
| Hoelzer, D | 2 |
| Goto, M | 1 |
| Onizawa, K | 1 |
| Yanagawa, T | 1 |
| Yamagata, K | 1 |
| Shinozuka, K | 1 |
| Nishikii, H | 1 |
| Koganemaru, H | 1 |
| Chiba, S | 1 |
| Bukawa, H | 1 |
| Echenique, IA | 1 |
| Vivekanandarajah, A | 1 |
| Bhatt, VR | 1 |
| Krishnarasa, B | 1 |
| Murukutla, S | 1 |
| Brenner, A | 1 |
| Gupta, S | 1 |
| Katusiime, C | 1 |
| Kambugu, A | 1 |
| Kriekard, P | 1 |
| Garcia, JA | 1 |
| Nardi-Korver, L | 1 |
| Krantz, MJ | 1 |
| Moayedi, Y | 1 |
| Venos, ES | 1 |
| Ghaffar, H | 1 |
| Gough, KA | 1 |
| Hicks, LK | 1 |
| Berger, M | 1 |
| Rockstroh, JK | 1 |
| Fätkenheuer, G | 2 |
| Seidel, E | 1 |
| Nickelsen, M | 1 |
| Wolf, T | 1 |
| Rieke, A | 1 |
| Schürmann, D | 3 |
| Schmidmaier, R | 1 |
| Planker, M | 1 |
| Alt, J | 1 |
| Engert, A | 1 |
| Arasteh, K | 2 |
| Tam, W | 1 |
| Henry, DH | 1 |
| Parekh, S | 1 |
| Cooley, T | 1 |
| Tulpule, A | 6 |
| Costello, RT | 2 |
| Brunet, C | 1 |
| Dignat-George, F | 1 |
| Sampol, J | 1 |
| Olive, D | 1 |
| Gastaut, JA | 3 |
| Gabarre, J | 4 |
| Rossi, G | 3 |
| Fasan, M | 2 |
| Schiantarelli, C | 1 |
| Nigra, E | 1 |
| Mena, M | 1 |
| Antinori, A | 2 |
| Ammassari, A | 1 |
| Talamini, R | 3 |
| Vaccher, E | 5 |
| di Gennaro, G | 2 |
| Theodossiou, C | 1 |
| Schwarzenberger, P | 1 |
| Watts, RG | 1 |
| Hilliard, LM | 1 |
| Berkow, RL | 1 |
| Boulanger, E | 2 |
| Brière, J | 1 |
| Gaulard, P | 1 |
| Droz, D | 1 |
| Oksenhendler, E | 4 |
| Pittaluga, S | 1 |
| Grant, N | 1 |
| Steinberg, SM | 1 |
| Kavlick, MF | 1 |
| Mitsuya, H | 1 |
| Franchini, G | 1 |
| Gutierrez, M | 2 |
| Raffeld, M | 1 |
| Jaffe, ES | 2 |
| Shearer, G | 1 |
| Yarchoan, R | 1 |
| Mak, YK | 1 |
| Chan, CH | 1 |
| Li, CK | 1 |
| Lee, MP | 1 |
| Tsang, YW | 1 |
| Romeu, J | 3 |
| Sirera, G | 1 |
| Mate, JL | 2 |
| Batlle, M | 3 |
| Grau, J | 1 |
| Millá, F | 4 |
| Feliu, E | 4 |
| Juncà, J | 1 |
| Rey, J | 1 |
| Charbonnier, A | 1 |
| Schiano de Colella, JM | 1 |
| Stoppa, AM | 1 |
| Poizot-Martin, I | 1 |
| Yamamoto, Y | 1 |
| Niino, H | 1 |
| Yasuoka, A | 1 |
| Kimura, S | 1 |
| Espina, BM | 2 |
| Pedro Santabarbara, AB | 1 |
| Palmer, M | 1 |
| Schiflett, J | 1 |
| Boswell, W | 1 |
| Smith, S | 1 |
| Waddington, TW | 1 |
| Aboulafia, DM | 2 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Carrington, NA | 1 |
| Bogetz, JF | 1 |
| Espina, B | 2 |
| Sherrod, A | 2 |
| Boswell, WD | 1 |
| Lieberman, RD | 1 |
| Nathwani, BN | 2 |
| Welles, L | 1 |
| Sharma, R | 1 |
| Abdou, S | 1 |
| Plymyer, MR | 1 |
| Rohatgi, C | 1 |
| Toffoli, G | 1 |
| Corona, G | 1 |
| Cattarossi, G | 1 |
| Boiocchi, M | 2 |
| Miles, SA | 1 |
| McGratten, M | 1 |
| Milling, DL | 1 |
| Lazarchick, J | 1 |
| Chaudhary, UB | 1 |
| Lim, ST | 1 |
| Karim, R | 1 |
| Scadden, DT | 1 |
| Lloveras, N | 1 |
| Fleisch, F | 1 |
| Reinhart, WH | 1 |
| Brand, B | 1 |
| Berger, C | 1 |
| del Potro, E | 1 |
| Abella, E | 2 |
| Plemons, JM | 1 |
| Benton, E | 1 |
| Rankin, KV | 1 |
| Larson, ML | 1 |
| Enschede, SH | 1 |
| Gregory, SA | 1 |
| Sawka, CA | 3 |
| Shepherd, FA | 3 |
| Franssen, E | 1 |
| Brandwein, J | 3 |
| Dotten, DA | 1 |
| Routy, JP | 1 |
| Walker, IR | 1 |
| St-Louis, J | 1 |
| Taylor, M | 1 |
| Arts, K | 1 |
| Crump, M | 1 |
| Foote, M | 1 |
| Nishio, M | 1 |
| Endo, T | 1 |
| Fujimoto, K | 2 |
| Sato, N | 1 |
| Sakai, T | 1 |
| Obara, M | 1 |
| Kumano, K | 2 |
| Minauchi, K | 1 |
| Koike, T | 1 |
| Youngster, I | 1 |
| Vaisben, E | 1 |
| Cohen, H | 1 |
| Nassar, F | 1 |
| Gisselbrecht, C | 2 |
| Reynes, J | 1 |
| Cheret, A | 1 |
| Bonnet, F | 1 |
| Billaud, E | 1 |
| Raphael, M | 2 |
| Lancar, R | 1 |
| Costagliola, D | 1 |
| Wolf, E | 1 |
| Van Lunzen, J | 2 |
| Stellbrink, HJ | 1 |
| Stoehr, A | 1 |
| Plettenberg, A | 1 |
| Jaeger, H | 1 |
| Noppeney, R | 2 |
| Goekbuget, N | 1 |
| Horst, HA | 1 |
| Tanaka, PY | 2 |
| Calore, EE | 2 |
| Hernàndez, DE | 1 |
| Hernàndez, AE | 1 |
| Crosswell, HE | 1 |
| Bergsagel, DJ | 1 |
| Yost, R | 1 |
| Lew, G | 1 |
| Simonelli, C | 2 |
| Northup, JK | 1 |
| Gadre, SA | 1 |
| Ge, Y | 1 |
| Lockhart, LH | 1 |
| Velagaleti, GV | 1 |
| Cheung, MC | 1 |
| Imrie, KR | 2 |
| Leitch, HA | 1 |
| Park-Wyllie, LY | 1 |
| Buckstein, R | 1 |
| Antoniou, T | 1 |
| Loutfy, MR | 1 |
| Dawson, MA | 1 |
| Schwarer, AP | 1 |
| McLean, C | 1 |
| Oei, P | 1 |
| Campbell, LJ | 1 |
| Wright, E | 1 |
| Shortt, J | 1 |
| Street, AM | 1 |
| Pessoa, VP | 1 |
| Pracchia, LF | 1 |
| Buccheri, V | 1 |
| Chamone, DA | 1 |
| Fieschi, C | 1 |
| Borie, R | 1 |
| Meignin, V | 1 |
| Daniel, MT | 2 |
| Gérard, L | 2 |
| Djunic, I | 1 |
| Jevtovic, DL | 1 |
| Ranin, J | 1 |
| Salemovic, D | 1 |
| Tomin, D | 1 |
| Mihaljevic, B | 1 |
| Nagajothi, N | 1 |
| Dham, SK | 1 |
| Gelfand, Y | 1 |
| Sanmugarajah, J | 1 |
| Fernández Canal, C | 1 |
| Campoamor Serrano, M | 1 |
| García Alcalde Fernández, ML | 1 |
| Pratesi, C | 1 |
| Zanussi, S | 1 |
| Bortolin, MT | 1 |
| Tedeschi, R | 1 |
| Marus, A | 1 |
| Caffau, C | 1 |
| Michieli, M | 1 |
| De Paoli, P | 1 |
| González-Barca, E | 1 |
| López-Guillermo, A | 1 |
| Gardella, S | 1 |
| López, A | 1 |
| García, M | 1 |
| Blinder, VS | 1 |
| Furman, RR | 1 |
| Mathew, S | 1 |
| Leonard, JP | 1 |
| Grünewald, T | 1 |
| Jautzke, G | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Shiramizu, B | 1 |
| Herndier, B | 2 |
| Hahn, J | 1 |
| Meeker, TC | 1 |
| Ng, V | 1 |
| Volberding, PA | 1 |
| McGrath, MS | 1 |
| Lévy, R | 1 |
| Colonna, P | 1 |
| Tourani, JM | 1 |
| Brice, P | 1 |
| Taillan, B | 2 |
| Andrieu, JM | 1 |
| Errante, D | 2 |
| Dolcetti, R | 1 |
| Gloghini, A | 1 |
| Serraino, D | 1 |
| Franceschi, S | 1 |
| Carbone, A | 2 |
| Garnier, G | 1 |
| Ferrari, E | 1 |
| Pesce, A | 1 |
| Vinti, H | 1 |
| Fuzibet, JG | 1 |
| Dujardin, P | 1 |
| Cheson, BD | 1 |
| Feigal, EG | 1 |
| Lichtman, SM | 1 |
| Brody, J | 1 |
| Kaplan, MH | 1 |
| Susin, M | 1 |
| Koduru, P | 1 |
| Goh, JC | 1 |
| Kutas, G | 1 |
| Warner, E | 2 |
| Burkes, R | 1 |
| Quirt, I | 1 |
| McGeer, A | 1 |
| Schoeppner, HL | 1 |
| Wong, DK | 1 |
| Bresalier, RS | 1 |
| Jäger, U | 1 |
| Karth, GD | 1 |
| Knapp, S | 1 |
| Tueni, C | 1 |
| Monpoux, F | 1 |
| Deville, A | 1 |
| Sirvent, N | 1 |
| Hoffman, P | 1 |
| Cottalorda, J | 1 |
| Mariani, R | 1 |
| Neumann, Y | 1 |
| Toren, A | 1 |
| Mandel, M | 1 |
| Martinowitz, U | 1 |
| Varon, D | 1 |
| Ramot, B | 1 |
| Ben-Bassat, I | 1 |
| Rechavi, G | 1 |
| Moses, AE | 1 |
| Rahav, G | 1 |
| Bloom, AI | 1 |
| Okon, E | 1 |
| Polliack, A | 1 |
| Maayan, S | 1 |
| Zimmerman, J | 1 |
| Patarca, R | 1 |
| Freidlander, A | 1 |
| Harrington, WJ | 1 |
| Cabral, L | 1 |
| Byrnes, JJ | 1 |
| Fletcher, MA | 1 |
| Valencia, ME | 1 |
| Moreno, V | 1 |
| Soriano, V | 1 |
| Polo, R | 1 |
| Verdejo, J | 1 |
| Laguna, F | 1 |
| González Lahoz, J | 1 |
| Powitz, F | 1 |
| Bogner, JR | 1 |
| Sandor, P | 1 |
| Zietz, C | 1 |
| Goebel, FD | 1 |
| Zoller, WG | 1 |
| Brockmeyer, NH | 1 |
| Pohl, G | 1 |
| Mertins, L | 1 |
| Davis, AJ | 1 |
| Goldstein, D | 1 |
| Milliken, S | 1 |
| Donisi, A | 1 |
| Casari, S | 1 |
| Re, A | 1 |
| Stellini, R | 1 |
| Cadeo, G | 1 |
| Carosi, G | 1 |
| Huhn, D | 1 |
| Mitrou, P | 1 |
| Nerl, C | 1 |
| Scheidegger, C | 1 |
| Knauf, W | 1 |
| Trenn, G | 1 |
| Kronawitter, U | 1 |
| Herbst, H | 1 |
| Vaquero, M | 2 |
| Gómez, J | 1 |
| Ridolfo, AL | 1 |
| Nosari, AM | 1 |
| Kerneis, Y | 1 |
| Mazzetti, F | 1 |
| Del Forno, A | 1 |
| Del Borgo, C | 1 |
| Turriziani, A | 1 |
| Ottaviani, F | 1 |
| Fantoni, M | 1 |
| Campbell, P | 1 |
| Iland, H | 1 |
| Gibson, J | 1 |
| Joshua, D | 1 |
| Chamberlain, MC | 1 |
| Kormanik, PA | 1 |
| Hansen, PB | 1 |
| Penkowa, M | 1 |
| Kirk, O | 1 |
| Skinhøj, P | 1 |
| Pedersen, C | 1 |
| Lisse, I | 1 |
| Kiss, K | 1 |
| Zhou, X | 1 |
| Hamilton-Dutoit, SJ | 1 |
| Dubreuil, ML | 1 |
| Levy, Y | 1 |
| Matheron, S | 1 |
| Cazals-Hatem, D | 1 |
| Chevret, S | 1 |
| Clauvel, JP | 1 |
| Jhala, DN | 1 |
| Medeiros, LJ | 1 |
| Lopez-Terrada, D | 1 |
| Jhala, NC | 1 |
| Krishnan, B | 1 |
| Shahab, I | 1 |
| Flores, A | 1 |
| Lee, J | 1 |
| Tang, S | 1 |
| Redden, D | 1 |
| Hamzeh, F | 1 |
| Scadden, D | 1 |
| Ambinder, R | 1 |
| Levine, A | 1 |
| Harrington, W | 1 |
| Grochow, L | 1 |
| Flexner, C | 1 |
| Tan, B | 1 |
| Straus, D | 1 |
| Pau, A | 1 |
| Horne, M | 1 |
| Wilson, W | 1 |
| Sturm, A | 1 |
| Reimer, J | 1 |
| Ross, B | 1 |
| Baumgart, D | 1 |
| Sundermann, T | 1 |
| Sadony, V | 1 |
| Gerken, G | 1 |
| Reiter, GS | 1 |
| Dharmapala, D | 1 |
| Young, LL | 1 |
| Sanchez, MN | 1 |
| Gill, PS | 1 |
| Vilchez, RA | 1 |
| Kozinetz, CA | 1 |
| Jorgensen, JL | 1 |
| Kroll, MH | 1 |
| Butel, JS | 1 |
| Bhama, JK | 1 |
| Azad, NS | 1 |
| Fisher, WE | 1 |
| Agbalika, F | 1 |
| Maarek, O | 1 |
| Grollet, L | 1 |
| Molina, JM | 1 |
| Sigaux, F | 1 |
| Harris, E | 1 |
| Paneesha, S | 1 |
| Jackson, N | 1 |
| Jones, L | 1 |
| Mahendra, P | 1 |
| Cornfield, DB | 1 |
| Papiez, JS | 1 |
| Lynch, JT | 1 |
| Rimsza, LM | 1 |
| Burkes, RL | 1 |
| Sutton, DM | 1 |
| Bomfim da Paz, R | 1 |
| Kölmel, HW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842] | Phase 1/Phase 2 | 107 participants (Actual) | Interventional | 2010-10-06 | Completed | ||
| Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas[NCT00118209] | Phase 3 | 524 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma[NCT00389818] | Phase 2 | 43 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| "Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: Stanford V Regimen For Low Risk Patients, EBVP Regimen For High Risk Patients"[NCT00003262] | Phase 2 | 30 participants (Anticipated) | Interventional | 1997-05-31 | Active, not recruiting | ||
| LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.[NCT02012088] | Phase 2 | 91 participants (Actual) | Interventional | 2013-10-11 | Active, not recruiting | ||
| Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma[NCT00003595] | Phase 3 | 120 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 75.6 |
| Phase II: DA-R-EPOCH | 82.2 |
The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 77.6 |
| Phase II: DA-R-EPOCH | 86.7 |
"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 67.5 |
| Phase II: DA-R-EPOCH | 76.2 |
Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days
| Intervention | Mg per day of Vorinostat (Number) |
|---|---|
| Phase I: VR-DA-EPOCH | 300 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cells/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -172 | -81 | -16 | 128 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 35.5 | -164.5 | -56 | 604 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -115 | 211 | 275 | 154 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per milliliter (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | 28 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | -14518 | -4517 | -55116 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -12.5 | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cell/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -218 | -190 | -175 | -84 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 92 | -39 | 76 | 169 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -9 | -29 | 31 | 31 |
Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | IU/mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 0 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -2436.1 | -1.92 | -1.92 | -1.15 |
| Phase II, DA-R-EPOCH | 0 | -0.28 | 0 | -2.7 |
| Phase II, VR-DA-EPOCH | -0.61 | -2.9 | -1.55 | -0.56 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) |
|---|---|
| 12-month follow-up | |
| Phase II: VR-DA-EPOCH | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) | ||
|---|---|---|---|
| At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | median change in copies per mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | -25 | -22.5 | -18 | -20 |
| Phase II: VR-DA-EPOCH | -20 | -87 | -20 | 0 |
The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-threatening | Severe | Moderate | Mild | |
| Phase II: DA-R-EPOCH | 20.0 | 28.9 | 31.1 | 17.8 | 0 |
| Phase II: VR-DA-EPOCH | 28.9 | 37.8 | 20.0 | 8.9 | 2.2 |
Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion
| Intervention | Liter/hour (Mean) | ||
|---|---|---|---|
| Doxorubicin | Etoposide | Vincristine | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 78.6 | 3.0 | 22.4 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 76.0 | 2.4 | 16.8 |
The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial Response | |
| Phase I: Arm C (VR-CHOP) Dose Level 1 | 100 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 83.3 | 16.7 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 83.3 | 16.7 |
The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm B - DA-EPOCH-R | 86.7 |
| Arm A - R-CHOP | 88.0 |
Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below. (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year OS rate | 5-year OS rate | |
| Arm A - R-CHOP | 85.7 | 78.5 |
| Arm B - DA-EPOCH-R | 86.5 | 77.5 |
"Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>~≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>~Appearance of any new lesion during or after completion of therapy.>~PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>~The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below." (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year PFS | 5-year PFS | |
| Arm A - R-CHOP | 75.5 | 66.0 |
| Arm B - DA-EPOCH-R | 78.9 | 68.0 |
(NCT00389818)
Timeframe: After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation
| Intervention | proportion of patients (Number) |
|---|---|
| DR-COP | 0.475 |
17 reviews available for prednisone and AIDS-Associated Lymphoma
| Article | Year |
|---|---|
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2017 |
Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir | 2013 |
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi | 2013 |
HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; CD4 Lymphocyt | 2008 |
[Recent advances and the treatment strategies of AIDS-related malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir | 2012 |
HIV-associated lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2012 |
Non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, AID | 2002 |
AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Thera | 2004 |
Multidrug resistance in AIDS-related lymphoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 2005 |
HIV-related lymphoma treated with maintenance thalidomide.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2005 |
Improving outcomes for patients with Burkitt lymphoma and HIV.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2008 |
Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1995 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
[Therapy of high-grade non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1994 |
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; | 2001 |
22 trials available for prednisone and AIDS-Associated Lymphoma
| Article | Year |
|---|---|
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2020 |
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2016 |
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2012 |
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; | 2002 |
Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2004 |
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 2004 |
Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2004 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Ly | 2005 |
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2007 |
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protoc | 1996 |
[Colony-stimulating factors and HIV-related neoplasms].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Cyclophosphamide | 1996 |
Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; | 1998 |
HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1998 |
Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Etop | 2000 |
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, High | 2001 |
Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
93 other studies available for prednisone and AIDS-Associated Lymphoma
| Article | Year |
|---|---|
Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2018 |
[Lymphomas associated with HIV infection in patients at the Hospital San Borja Arriarán /Fundación Arriarán 2001-2008, Santiago, Chile].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chile; Cyclophosphamide; Doxorubicin; F | 2013 |
Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality Therapy; | 2014 |
Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; | 2013 |
AIDS-lymphoma (ARL): one more step along the way.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-De | 2014 |
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2014 |
Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis.
Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2014 |
Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cycl | 2014 |
Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2016 |
Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; HIV In | 2016 |
Treatment-responsive Diffuse Pancreatic Swelling: Seems Similar, Yet Is It?
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2016 |
[Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection].
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophospha | 2008 |
Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therap | 2008 |
Chemotherapy as treatment for colo-colonic intussusception associated with acquired immune deficiency syndrome-related lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Cyclophosphamide; Doxorubicin; Eto | 2011 |
Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2010 |
Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 2010 |
Febrile neutropenia in a HIV positive individual post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus | 2010 |
[Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2010 |
Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Dox | 2011 |
Human immunodeficiency virus-associated Burkitt's lymphoma in oral cavity of Japanese patient.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2012 |
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clini | 2012 |
Right upper quadrant pain and mass in a 41-year-old previously healthy man: a presenting feature of HIV-associated extranodal diffuse large B cell lymphoma with cardiac involvement.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2012 |
A rare entity of primary extranodal diffuse large B cell lymphoma of the lower limb calf in an HIV-infected young adult on highly active antiretroviral therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2012 |
Tumor melt: primary effusion lymphoma of the heart.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Echocardiogra | 2012 |
Paying more than lip service to an oral lesion: a case of plasmablastic lymphoma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Pro | 2012 |
Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Combined Modality Thera | 2002 |
Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Chemotherap | 2002 |
HHV8-related non-Hodgkin's lymphoma of the spermatic cord in a patient with HIV-associated multicentric Castleman disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Castleman Dis | 2003 |
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2003 |
Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2002 |
Anorectal lymphoma without effusion associated with human herpesvirus-8 and type 1 Epstein-Barr virus in an HIV-infected patient.
Topics: AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasm | 2003 |
Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2003 |
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2004 |
KSHV/HHV8-associated lymphoma simulating anaplastic large cell lymphoma.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derive | 2004 |
Normal grief and bereavement: letters from home.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Attitude to Death; Bereavement; Correspondenc | 2004 |
Disseminated plasmablastic lymphoma.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti | 2004 |
Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Topics: Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2005 |
Primary mediastinal large B-cell lymphoma in an HIV-infected patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; | 2005 |
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2005 |
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2005 |
Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA, Viral; Doxor | 2005 |
Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ant | 2005 |
Non-Hodgkin's lymphoma and acquired immune deficiency syndrome (AIDS). A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Facial Neoplasms; Fat | 2005 |
Current status of the treatment of HIV-associated lymphoma.
Topics: Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2004 |
Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.
Topics: Agammaglobulinemia; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, M | 2005 |
An unusual cause of pleural effusion.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diff | 2006 |
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2006 |
P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Antineoplastic Combined Chem | 2007 |
Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fever; | 2006 |
Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2008 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretro | 2007 |
Hodgkin lymphoma among patients infected with HIV in post-HAART era.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2007 |
Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; | 2008 |
Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2007 |
[Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Esophageal Neo | 2007 |
Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Combined Chemotherapy P | 2008 |
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blotting, Southern; CD4 Lymphocyte Count; | 1995 |
Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequ | 1995 |
MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1993 |
Clinical trials referral resource. AIDS-related non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 1993 |
Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dexametha | 1993 |
HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gastro | 1995 |
Primary small bowel lymphoma manifested as obstructive jaundice in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cholangio | 1995 |
[B-lymphoma in a child with AIDS. Therapeutical implications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Doxorubicin; Dru | 1993 |
Favorable response of pediatric AIDS-related Burkitt's lymphoma treated by aggressive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 1993 |
Primary lymphoma of the esophagus in a patient with AIDS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Esophageal Di | 1995 |
Gastrointestinal lymphomas in patients with AIDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Endoscopy, Gas | 1997 |
Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Burki | 1997 |
Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; H | 1998 |
International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1998 |
Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Epirubicin; Femal | 1999 |
Non-Hodgkin's lymphoma of the maxillary sinus in a patient with acquired immunodeficiency syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents; Cyclophosphamide; Doxorubicin; | 1998 |
Syngeneic stem cell transplantation for HIV-related lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hematopoietic | 1999 |
AIDS-related central nervous system lymphomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neopl | 1999 |
Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Denmark; DNA, Viral; Doxoru | 2000 |
Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte | 2000 |
Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2000 |
Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2001 |
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy, Needl | 2001 |
[AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Ph | 2001 |
Acute abdomen in an HIV-positive man.
Topics: Abdominal Pain; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D | 1997 |
Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2002 |
AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bleomycin; CD | 2002 |
Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male.
Topics: Abscess; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Biopsy, Needle; Cyclo | 2002 |
Burkitt's lymphoma: single-centre experience with modified BFM protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2002 |
Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophospha | 2002 |
Meningitis with Burkitt like B-cell lymphoma in HIV infection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 1992 |